How are MAO-B inhibitors used in Parkinson’s disease treatment?

The Parkinson’s Protocol™ By Jodi Knapp Parkinson’s disease cannot be eliminated completely but its symptoms can be reduced, damages can be repaired and its progression can be delayed considerably by using various simple and natural things. In this eBook, a natural program to treat Parkinson’s disease is provided online. it includes 12 easy steps to repair your body and reduce the symptoms of this disease. The creator of this program has divided into four segments to cover a complete plan to treat this disease along with improving your health and life by knowing everything about this health problem. The main focus of this program is on boosting the levels of hormone in your brain by making e a few easy changes in your lifestyle, diet, and thoughts

How are MAO-B inhibitors used in Parkinson’s disease treatment?

MAO-B inhibitors are a class of medications used in the treatment of Parkinson’s disease to help manage its symptoms. These inhibitors work by blocking the action of monoamine oxidase B (MAO-B), an enzyme responsible for breaking down dopamine in the brain. By inhibiting this enzyme, MAO-B inhibitors increase and prolong the effects of dopamine, thereby helping to alleviate the motor symptoms associated with Parkinson’s disease.

Key MAO-B Inhibitors Used in Parkinson’s Disease

Selegiline (Eldepryl, Zelapar)
Rasagiline (Azilect)
Safinamide (Xadago)

How MAO-B Inhibitors Work

Mechanism of Action: MAO-B inhibitors selectively inhibit the MAO-B enzyme, which is primarily responsible for breaking down dopamine in the brain. By preventing dopamine degradation, these drugs increase dopamine availability, improving communication between neurons in the motor control centers of the brain.
Enhancing Levodopa Effectiveness: In addition to being used as monotherapy in the early stages of Parkinson’s disease, MAO-B inhibitors are often added to levodopa treatment in more advanced stages. This combination can help reduce the “wearing-off” effect seen with long-term levodopa use, where the drug’s effectiveness diminishes before the next dose is due.

Clinical Use of MAO-B Inhibitors

Early Stages of Parkinson’s Disease:
- Monotherapy: MAO-B inhibitors can be used alone in the early stages of Parkinson’s disease, particularly in younger patients or those with milder symptoms. By increasing dopamine levels, they help manage early motor symptoms, such as mild tremors or bradykinesia.
- Delaying Levodopa Therapy: By providing symptom relief in the early stages, MAO-B inhibitors can delay the need for levodopa, postponing the onset of levodopa-related complications like dyskinesia.
Advanced Parkinson’s Disease:
- Adjunct to Levodopa: In more advanced stages of Parkinson’s, MAO-B inhibitors are often used in combination with levodopa. This combination helps to extend the duration of levodopa’s effects, reducing motor fluctuations and improving “on” time (periods when symptoms are well-controlled).
- Managing Motor Fluctuations: MAO-B inhibitors can be particularly useful in managing motor fluctuations in patients who experience “off” periods where symptoms return before the next levodopa dose.

Side Effects of MAO-B Inhibitors

Common Side Effects: These may include nausea, dry mouth, dizziness, and headaches. Selegiline, in particular, can also cause insomnia, especially if taken later in the day, due to its amphetamine-like metabolites.
Interaction with Tyramine-Rich Foods: Traditionally, MAO inhibitors required dietary restrictions to avoid hypertensive crises caused by tyramine-rich foods. However, MAO-B inhibitors are selective for the MAO-B enzyme and generally do not require such dietary restrictions, although caution is still advised, particularly at higher doses.
Neuropsychiatric Effects: Some patients may experience confusion, hallucinations, or other neuropsychiatric symptoms, particularly in older adults or those with pre-existing cognitive impairment.

Advantages of MAO-B Inhibitors

Neuroprotective Potential: There is some evidence to suggest that MAO-B inhibitors may have neuroprotective effects, potentially slowing the progression of Parkinson’s disease, although this is still a subject of ongoing research.
Less Dyskinesia: Unlike levodopa, MAO-B inhibitors are less likely to cause dyskinesia when used as monotherapy in the early stages of Parkinson’s.

Disadvantages and Limitations

Milder Symptom Relief: While MAO-B inhibitors can be effective in managing mild symptoms, they are generally less potent than levodopa and may not provide sufficient relief for patients with more severe motor symptoms.
Limited Use as Disease Progresses: As Parkinson’s disease progresses, the effectiveness of MAO-B inhibitors as monotherapy decreases, necessitating the addition of other medications like levodopa.

Conclusion

MAO-B inhibitors play an important role in the management of Parkinson’s disease, particularly in the early stages or as an adjunct to levodopa therapy in more advanced cases. By inhibiting the breakdown of dopamine, these drugs help to alleviate motor symptoms and improve quality of life for patients. However, their use requires careful consideration of potential side effects and interactions, and they are typically part of a broader treatment strategy tailored to the individual needs of the patient.

Jodi Knapp